United States

People: BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

22 Sep 2017
Change (% chg)

$-0.03 (-0.57%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Staab, Thomas 

Mr. Thomas R. Staab, II, is Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer of BioCryst Pharmaceuticals, Inc. Thomas joined BioCryst in July 2011 as its Chief Financial Officer and Treasurer. Mr. Staab most recently served as Executive Vice President, Chief Financial Officer and Treasurer of Inspire Pharmaceuticals from May 2003 through its $430 million acquisition by Merck & Co., Inc. in May 2011. Prior to joining Inspire, he held senior financial positions of acting Chief Financial Officer and Treasurer at Triangle Pharmaceuticals, Inc. through its $480 million acquisition by Gilead Sciences, Inc. in 2003. Before joining Triangle, Mr. Staab spent eight years working for PriceWaterhouseCoopers LLP providing audit and business advisory services to national and multi-national corporations in the biotechnology, pharmaceutical, pulp and paper and communications industries. Mr. Staab currently serves on the Executive Committee of the Board of Directors of the North Carolina Biosciences Organization (“NCBIO”) and is a member of its Audit Committee. He has received several awards for his contribution and leadership to other organizations through NCBIO. He is a Certified Public Accountant and received a B.S. in Business Administration and a Masters of Accounting from the University of North Carolina at Chapel Hill.

Basic Compensation

Total Annual Compensation, USD 575,175
Restricted Stock Awards, USD 583,200
Long-Term Incentive Plans, USD --
All Other, USD 987,413
Fiscal Year Total, USD 2,145,790

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Robert Ingram


Jon Stonehouse


Thomas Staab


Yarlagadda Babu


Lynne Powell


William Sheridan

As Of  30 Dec 2014